April 2009
Volume 50, Issue 13
ARVO Annual Meeting Abstract  |   April 2009
Long-Term Therapeutic Effects of a Nanoparticle-Mediated Angiogenic Inhibitor on Diabetic Retinopathy
Author Affiliations & Notes
  • Y. Hu
    OUHSC, Oklahoma City, Oklahoma
  • K. Park
    OUHSC, Oklahoma City, Oklahoma
  • Y. Chen
    OUHSC, Oklahoma City, Oklahoma
  • A. S. Mayo
    Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska
  • U. B. Kompella
    Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska
  • R. Longeras
    OUHSC, Oklahoma City, Oklahoma
  • J.-X. Ma
    OUHSC, Oklahoma City, Oklahoma
  • Footnotes
    Commercial Relationships  Y. Hu, None; K. Park, None; Y. Chen, None; A.S. Mayo, None; U.B. Kompella, None; R. Longeras, None; J.-X. Ma, None.
  • Footnotes
    Support  NIH EY015650, EY012231, and P20RR024215;Oklahoma Center for the Advancement of Science & Technology (AR06.2-041)
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 2412. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Hu, K. Park, Y. Chen, A. S. Mayo, U. B. Kompella, R. Longeras, J.-X. Ma; Long-Term Therapeutic Effects of a Nanoparticle-Mediated Angiogenic Inhibitor on Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2412.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Abnormal retinal vascular leakage is one of the major pathological changes in diabetic retinopathy (DR). Our previous studies have shown that plasminogen kringle 5 (K5), a natural angiogenic inhibitor, effectively reduced retinal vascular leakage in DR animal models. However, the effect of K5 was transient after a single intravitreal injection. The purpose of this study is to develop a sustained delivery system and explore therapeutic potential of nanoparticle-mediated delivery of K5.

Methods: : An expression plasmid of K5 was encapsulated with poly lactide-co-glycolide to form K5 nanoparticles (K5-NP). Adult Brown Norway rats were given a single intraperitoneal injection of streptozotocin (STZ) to induce diabetes. Expression and secretion of K5 were determined by Western blot analysis and immunohistochemistry. Vascular permeability was quantified by measuring leakage of FITC-albumin or Evans blue dye-albumin complex from the blood vessels into the retina. Possible toxicities were evaluated using histology examination and electroretinogram (ERG) recording.

Results: : An intravitreal injection of K5-NP resulted in high-level expression of K5 in the inner retina of rats, and the expression lasted for the entire 4 weeks analyzed. Significant reductions of retinal vascular leakage was observed 4 weeks after a single intravitreal injection of K5-NP, when compared to control group injected with Control nanoparticles in STZ-induced diabetic rats. Moreover, K5-NP attenuated retinal inflammation in STZ rats. K5-NP injection did not lead to any detectable toxicities to retinal structure and function.

Conclusions: : K5-NP mediates efficient and sustained K5 expression in the retina and has therapeutic potential in diabetic macular edema.

Keywords: diabetic retinopathy • retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.